



PRIOR AUTHORIZATION REQUEST FORM

BEYFORTUS™

For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance 385-425-5094.

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:	
DOB:	Gender:	Physician:	
Office Phone:	Office Fax:	Office Contact:	
Height/Weight:			
Product being requested: <input type="checkbox"/> Beyfortus™ (nirsevimab-alip)			
Dosing/Frequency: _____			
If the request is for reauthorization, proceed to reauthorization section			
Questions	Yes	No	Comments/Notes
1. Is this request for an expedited review? By checking the “ Yes ” box to request an expedited review (24 hours), you are certifying that applying the standard review time frame (72 hours) may place the member's life, health, or ability to regain maximum function in serious jeopardy.	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the member less than 8 months of age born during or entering their first Respiratory Syncytial Virus (RSV) season?	<input type="checkbox"/>	<input type="checkbox"/>	If yes, prior authorization is NOT required.
3. Is the member 8-19 months of age entering their second RSV season?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member have chronic lung disease of prematurity, defined as gestational age < 32 weeks AND required medical support (chronic corticosteroid therapy, diuretic therapy or supplemental oxygen) any time during the 6-month period before the start of the second RSV season?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Is the member expected to be profoundly immunocompromised during the current RSV season?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Does the member have cystic fibrosis with manifestations of severe lung disease (i.e., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) or have a weight-for-length < 10 th percentile?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Will the member be undergoing cardiac surgery with cardiopulmonary bypass? <i>Date of surgery:</i> _____ <i>Date of most recent Beyfortus dose:</i> _____	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

Additional information:

Physician's Signature:

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM- 154

Origination Date: 09/12/2023

Reviewed/Revised Date: 09/18/2024

Next Review Date: 09/18/2025

Current Effective Date: 10/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.